New Market - January 15, 2025
ALK’s ACARIZAX approved in Europe for treatment of young children
ALK has announced that its European regulatory filing for ACARIZAX (house dust mite sublingual allergy immunotherapy tablet) in young children aged five to 11 has been approved by the health authorities in 21 EU countries via a type II variation procedure.
New Market - December 3, 2024
American IonQ opens operation in Gothenburg
IonQ has set up in Gothenburg, primarily through a new development center at AstraZeneca BioVentureHub.
New Market - November 29, 2024
ScandiDos expands with new reference center
ScandiDos has announced that the prestigious Hospital Central de la Defensa Gómez Ulla (HCD Gómez Ulla) in Madrid has become a reference center for ScandiDos and the Delta4 family of products.
MedTech Business - November 13, 2024
Capitainer expands operations with enhanced US presence
Capitainer has announced the establishment of Capitainer Inc. in the United States. This expansion will enhance customer service and streamline order processing for the company’s growing US market, further strengthening Capitainer’s goal to become the gold standard and global leader in self-sampling, the company states.
Agreement - November 11, 2024
ALK licenses rights to neffy
ALK has entered into a strategic license agreement with US-based ARS Pharmaceuticals.
Intellectual Property - October 31, 2024
Mucocort receives additional patent approval in China
Mucocort has been granted a patent in China for its product/technology, which has previously been approved under the European Patent System (EPC).
